Products developed with Acura's proprietary Aversion® Technology are intended to deter or discourage common methods of prescription drug abuse:
On June 17, 2011, the FDA approved Oxecta™ (oxycodone HCl, USP) Tablets CII (formerly Acurox®) for marketing in the United States. Full prescribing information can be accessed
Acura has entered into a license agreement with King Pharmaceuticals Research & Development, Inc., a subsidiary of Pfizer, Inc. to develop and commercialize opioid analgesic products utilizing our proprietary Aversion® Technology, including Oxecta™ Tablets.
Acura's strategy includes continued investment in novel solutions to prescription drug abuse. We have three issued U.S. patents covering our Aversion® Technology with numerous US and international patent applications pending.